Navigation Links
Sinapis Pharma Completes Phase I Trial
Date:7/11/2011

JACKSONVILLE, Fla., July 11, 2011 /PRNewswire/ -- Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.  The Phase I trial entitled " A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetics of Oral and Intravenous Administration of Methamphetamine Hydrochloride in Healthy Volunteers" was conducted at Prism Research in St. Paul, MN.

This was a single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover study of the safety and pharmacokinetics of oral and IV administration of methamphetamine HCl in six healthy volunteers.  Subjects were randomized 1:1 to receive a single oral dose of methamphetamine HCl (5 mg Desoxyn® tablet) or a single IV dose of methamphetamine HCl (5 mL of 0.5 mg/mL methamphetamine HCl injection infused over one hour for a total dose of 2.5 mg), and then crossed over to the other treatment (i.e., IV or oral dose, respectively) after a 10 day washout period.  Subjects received a single dose of study drug on Day 1 of each of the two treatment periods.

The trial successfully demonstrated the safety of an IV infusion of Methamphetamine and produced the IV infusion pharmacokinetics needed to initiate Phase IIa clinical studies in stroke patients.

Sinapis plans to initiate its Phase IIa trial in stroke patients before year end.

Dr Donald Picker, Sinapis CEO, said  "We are very pleased  and excited to complete the next step in the development of this drug for stroke and traumatic brain injury patients. We are eager to begin the proof of principle trials in these very important indications where there are currently no effective treatments."

Sinapis Pharma, Inc. (www.sinapispharma.com'/>"/>

SOURCE Sinapis Pharma, Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
2. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
3. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
4. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
5. PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation
6. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
7. Genesis Biopharma Conference Call and Webcast Reminder
8. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
9. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
10. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
11. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Underscores Morphotek,s Commitment to the Development of Farletuzumab ... Specialty Development and Manufacturing SolutionsEXTON, Pa. and BASEL, ... of Eisai Corporation of North America, and Lonza ... executed a manufacturing services agreement to support the ...
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... signed an agreement-in-principle to ensure the valorization and the operation ... the Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de ...
Cached Biology Technology:Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat to ... declines of amphibians, bats, corals, bees and snakes. ... published in the prestigious journal Nature ... resistance to a deadly chytrid fungus implicated in ... is important because it is the basis of ...
(Date:7/9/2014)... 2014Biofuels derived from the oils produced by algae may ... achieve this goal, optimization of cost effective strategies for ... is needed. Sapphire Energy has developed an innovative solution ... cultivation systems, described in Industrial Biotechnology , a ... article is available on the Industrial Biotechnology ...
(Date:7/9/2014)... Genome Atlas (TCGA) Research Network have identified novel ... adenocarcinoma, the most common subtype of lung cancer. ... number of possible therapeutic targets for this disease ... with treatable mutations because many potent cancer drugs ... is jointly funded and managed by the National ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... Hill, CA Bowman Design Group, an integrated marketing and ... marketing, is the first and only company in the ... the German exhibition and events industry association. Third party ... company met or exceeded goals set for nine criteria ...
... DIEGO At the Plenary Session of the American ... AAPS President Tony DeStefano, Ph. D. will present the ... the pharmaceutical sciences: AAPS Ligand Binding Assays ... Alison Joyce, B.S. (lead author); Sheldon Leung, Ph.D.; ...
... When determining the potential effects pesticides could pose ... Protection Agency, National Marine Fisheries Service (NMFS), and ... common scientific approach, says a new report from ... should use a risk assessment approach that addresses ...
Cached Biology News:Bowman Design Group is first US company awarded German FAMAB 'Sustainable Company' certification 2AAPS announces 2013 National Biotechnology Conference award winners 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 3
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... is from the C-terminal end of the mouse retinoic acid receptor beta ... to 448 of RAR*. The sequence of PEP-005 is (amino to ... P - S - S - V - E - N - ... P - L - L - Q (The N-terminal cysteine has ...
... use of small interfering RNA (siRNA) molecules ... interference (RNAi) pathway have generated tremendous interest ... siRNA for experimental use can be synthesized ... then transfected into the target cells in ...
... is an automated hybridization system for the ... both the hybridization and post hybridization washing ... single instrument can process up to 12 ... has multi-protocol software, enabling the user to ...
Biology Products: